Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 1, 1996, Pages 230-233

  Cañas, Elias ^a   Pachon, Jeronimo ^a   Garcia Pesquera, Felipe ^a   Castillo, Juan R ^a   Viciana, Pompeyo ^a   Cisneros, Jose M ^a   Jimenez Mejias, Manuel E ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030025641     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.1.230     Document Type: Article

References (28)

1. Anand, N. 1975. Sulfonamides and sulfones, p. 668. In J. W. Corcoran, and F. E. Hahn (ed.), Antibiotics III. Mechanism of action of antimicrobial and antitumor agents. Springer-Verlag, Berlin.
2. Blum, M. R., S. H. T. Liao, S. S. Good, and P. de Miranda. 1988. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med 85(Suppl. 2A):189-194.
3. Burchall, J. J. 1975. Trimethoprim and pyrimethamine, p. 304. In J. W Corcoran and F E. Hahn (ed.), Antibiotics III. Mechanism of action of antimicrobial and antitumor agents. Springer-Verlag, Berlin.
4. Burger, D. M., P. L. Meenhorst, C. H. W. Koks, and J. H. Beijnen. 1993. Drug interactions with zidovudine. AIDS 7:445-460.
5. Centers for Disease Control. 1989. Guidelines for prophylaxis against Pneumocystis carinit pneumonia for persons infected with human immunodeficiency virus. Morbid. Mortal. Weekly Rep. 38(S5):1-9.
6. Centers for Disease Control. 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid. Mortal. Weekly Rep. 41(RR-17):1-19.
7. Chatton, J. Y., A. Munafo, J. P. Chave, F. Steinhäuslin, F. Roch-Ramel, M. P. Gluaser, and J. Biollaz. 1992. Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. Br. J. Clin. Pharmacol. 34:551-554.
8. Cload, P. A. 1989. A review of the pharmacokinetics of zidovudine in man J. Infect 18(Suppl. 1):67-72.
9. Collins, J. M., and J. D. Unadkat. 1989. Clinical pharmacokinetics of zidovudine: an overview of current data. Clin. Pharmacokinet. 1:1-9
10. Feinberg, J., C. Leport, and P. Reiss. 1991. Update in opportunistic infections. AIDS 5(Suppl 2):S195-S202.
11. Furman, P. A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. N. Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, and D. W. Barry. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad Sci. USA 83:8333-8337.
12. Good, S. S., D. T. Durack, and P. de Miranda. 1986. Biotransformation in various species and in humans of 3′-azido-3′-deoxy-thymidine, a potential agent for the treatment of AIDS. Fed Proc. 45:444.
13. Klecker, R. W., J. M. Collins, R. Yarchoan, R. Thomas, J. F. Fenkins, S. Broder, and C. E. Myers. 1987. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases Clin Pharmacol. Ther. 41:407-412.
14. Langtry, H. D., and D. M. Campoli-Richards, 1989. Zidovudine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 37:408-450.
15. Laskin, O. L., P. de Miranda, and M. R. Blum. 1989. Azidothymidine steady-slate pharmacokinetics in patients with AIDS and AIDS-related complex J Infect. Dis. 159:745-747.
16. Lee, B. L., S. Safrin, V. Makrides, N. L. Benowitz, J. G. Gambertoglio, and J. Mills. 1992. Trimethoprim decreases the renal clearance of zidovudine. Clin. Pharmacol. Ther. 51:183 (Abstract )
17. MacLeod, R., V. A. Eagling, S. M. Sim, and D. J. Back. 1991 In vitro inhibition studies of the glucuronidation of 3′-azido-3′-deoxythymidine by human liver UDP-glucuronosyl transferase. Biochem Pharmacol. 43:382-386
18. Martin, M. A., P. H. Cox, K. Beck, C. M. Styer, and G. N. Beall. 1992 A comparison of the effectiveness of three regimens in the prevention of Pneumocystis cannti pneumonia in human immunodeficiency virus-infected patients Arch. Intern Med. 152:523-528
19. Morse, G. D., M. J. Shelton, and A. M. O'Donnell. 1993. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin. Pharmacokinet. 24:101-123
20. Pachon, J., P. Viciana, J. M. Cisneros, F. García-Pesquera, J. R. Castillo, and E. Cañas. 1993. Estudio farmacocinético de la zidovudina en adictos a drogas parenterales con infección por el virus dc la immunodeficiencia humana. Med. Clin. (Barcelona) 100:46-49.
21. Pazin, G. J., R. J. Ptacheinski, B. Schillinger, D. K. McMahon, J. A. Armstrong, and M. Ho. 1990 Interactive pharmacokinetics of zidovudine and prophylactic or therapeutic dosages of trimethoprim-sulfamethoxazole. abstr. S.B 429. In Program and Abstracts of the Sixth International Conference on AIDS University of California, San Francisco.
22. Quinn, R. P., O. Orban, and S. Tadepalli. 1989. Radioimmunoassay for retrovir, an anti-human immunodeficiency virus drug. J. Immunoassay 10: 177-189.
23. Resetar, A., D. Minick, and T. Spector. 1991. Glucuronidation of 3′-azido-3′-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. Biochem. Pharmacol. 42:559-568.
24. Schumaker, R. C. 1986. PKCALC: a basic interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab. Rev. 17:331-348.
25. Sim, S. M., D. J. Back, and A. M. Breckenridge. 1991. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine, AZT) hy human liver microsomes. Br J. Clin. Pharmacol. 32:17-21.
26. Singlas, E., J. C. Pioger, A. M. Taburet, S. Solaneri, and J. P. Fillastre. 1989. Comparative pharmacokinetics of zidovudine and its metabolite in healthy subjects and HIV seropositive patients Eur. J. Clin. Pharmacol. 36:639-640.
27. St. Clair, M. H., C. A. Richards, T. Spector, K. J. Weinhold, W. H. Miller, A. J. Langlois, and P. A. Furman. 1987. 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob. Agents Chemother. 31:1972-1977.
28. Yarchoan, R., H. Mitsuya, C. E. Myers, and S. Broder. 1989. Clinical pharmacology of 3′-azido-3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N. Engl. J. Med 321:726-738.